研究ChAdOx1在疫苗诱导的血栓性血小板减少症背景下的内皮细胞转导及六邻体与血小板因子4的结合
腺病毒载体SARS-CoV-2疫苗(如Vaxzevria和Jcovden)大规模接种后,约1:200 000受种者出现疫苗诱导的血栓性血小板减少症。本研究通过蛋白序列比对和体外转导实验评估ChAdOx1感染并激活内皮细胞的能力,并用表面等离子共振检测ChAdOx1六邻体与PF4的静电相互作用。结果显示ChAdOx1以柯萨奇腺病毒受体非依赖方式高效转导内皮细胞但不引起激活,纯化六邻体蛋白与PF4的结合亲和力与完整ChAdOx1衣壳相似。
要点
- 约1:200 000接种腺病毒载体SARS-CoV-2疫苗者发生疫苗诱导的血栓性血小板减少症。
- ChAdOx1以柯萨奇腺病毒受体非依赖方式高效转导内皮细胞,但未导致内皮细胞激活。
- 纯化ChAdOx1六邻体蛋白与PF4结合,亲和力与完整ChAdOx1衣壳相似。
核心结论
- 数据证实需要开发非PF4结合的腺病毒衣壳并评估其减轻疫苗诱导的血栓性血小板减少症相关不良事件的潜力。
研究设计与样本
- 使用蛋白序列比对工具和体外转导实验评估ChAdOx1感染内皮细胞的能力。
- 进一步测定ChAdOx1感染对内皮细胞激活的影响。
- 使用表面等离子共振评估ChAdOx1六邻体与PF4之间的静电相互作用。
主要发现
- ChAdOx1缺乏主要细胞进入受体柯萨奇腺病毒受体,但仍以柯萨奇腺病毒受体非依赖方式高效转导内皮细胞。
- 该转导未导致内皮细胞激活。
- 从ChAdOx1制品中纯化的六邻体蛋白与PF4结合,亲和力与先前报道的完整ChAdOx1衣壳相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccines against SARS-CoV-2 have been essential in controlling COVID-19-related mortality and have saved millions of lives. Adenoviral (Ad)-based vaccines have been an integral part of this vaccine campaign, with licensed vaccines based on the simian Y25 isolate (Vaxzevria; AstraZeneca) and human Ad type 26 (Jcovden; Janssen) widely adopted. As part of the largest global vaccination program ever undertaken, cases of vaccine-induced thrombotic thrombocytopenia have been described in approximately 1:200 000 vaccinees administered with Ad-based SARS-CoV-2 vaccines. OBJECTIVES: The mechanism underpinning these adverse events remains to be completely delineated but is characterized by elevated autoantibodies against platelet factor 4 (PF4), which, when complexed with PF4, cluster and bind FcγRIIa on platelets and induce thrombus formation. Here, we investigated the ability of ChAdOx1 to transduce and activate endothelial cells (ECs). METHODS: Using protein sequence alignment tools and in vitro transduction assays, the ability of ChAdOx1 to infect ECs was assessed. Furthermore, the ability of ChAdOx1 infection to activate ECs was determined. Finally, using surface plasmon resonance, we assessed the electrostatic interactions between the ChAdOx1 hexon and PF4. RESULTS: Despite lacking the primary cell entry receptor, coxsackie and adenovirus receptor, ChAdOx1 efficiently transduced ECs in a coxsackie and adenovirus receptor-independent manner. This transduction did not result in EC activation. Purified hexon protein from ChAdOx1 preparations did, however, bind PF4 with a similar affinity to that previously reported for the whole ChAdOx1 capsid. CONCLUSION: These data confirm the need to develop non-PF4 binding Ad capsids and assess their potential to mitigate adverse events associated with vaccine-induced thrombotic thrombocytopenia.
引用
- Lovatt C, Frängsmyr L, Swift EA, et al. Investigating endothelial cell transduction and hexon: platelet factor 4 binding of ChAdOx1 in the context of vaccine-induced thrombotic thrombocytopenia. J Thromb Haemost. 2025. PMID: 40516826. doi:10.1016/j.jtha.2025.06.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。